Quantcast
Last updated on April 18, 2014 at 16:07 EDT

Latest Paclitaxel Stories

2013-01-22 20:21:04

MELBOURNE, Australia, Jan. 22, 2013 /PRNewswire/ -- Australian biopharmaceutical company Specialised Therapeutics Australia announces that a phase III clinical trial of world leading breast cancer drug ABRAXANE(®) (nanoparticle albumin-bound paclitaxel) in combination with current standard of care gemcitabine in patients with advanced pancreatic cancer has demonstrated substantially improved survival times, with double the number of patients surviving two...

2013-01-22 20:21:01

Virginia G. Piper Cancer Center data presented at San Francisco ASCO symposium SCOTTSDALE, Ariz., Jan. 22, 2013 /PRNewswire-USNewswire/ -- A multi-center Phase III clinical trial demonstrates that Abraxane (nab-paclitaxel) plus gemcitabine is the first combination of cancer drugs to extend survival of late-stage pancreatic cancer patients compared to standard treatment. (Photo: http://photos.prnewswire.com/prnh/20120201/DC45876) The MPACT (Metastatic Pancreatic...

2013-01-10 20:21:52

EXTON, Pa., Jan. 10, 2013 /PRNewswire/ -- Morphotek(®) Inc., a wholly-owned subsidiary of Eisai Inc., announced today top-line results from a Phase III study of its investigational agent farletuzumab (MORAb-003) in combination with carboplatin and a taxane in patients with platinum-sensitive epithelial ovarian cancer in first relapse. The study found that farletuzumab in combination with carboplatin and a taxane did not meet the study's primary endpoint of progression-free survival...

2013-01-11 02:20:01

Tokyo, Jan 11, 2013 - (JCN Newswire) - Eisai Co., Ltd. announced today the preliminary results of its global Phase III study (Study FAR 131, MORAb-003-004) of farletuzumab (MORAb-003), an investigational compound under development at its U.S. subsidiary, Morphotek, Inc., in patients with platinum-sensitive epithelial ovarian cancer in first relapse.The study was a multicenter, randomized, double-blind, placebo-controlled, parallel-group comparative study of 1,100 patients with...

2013-01-07 08:31:08

BUFFALO, N.Y., Jan. 7, 2013 /PRNewswire/ -- Kinex Pharmaceuticals and Hanmi Pharmaceutical announced today that the first patient has been enrolled in Hanmi's Phase Ib / IIa clinical trial in Korea. Kinex's dual Src/pretubulin Inhibitor, KX01, is being combined with intravenous (IV) paclitaxel to treat solid tumor patients in Phase Ib and then gastric and breast cancer patients in Phase IIa. KX01 (KX2-391) is an once daily, orally administered potent small molecule Src kinase/pretubulin...

2012-12-03 04:20:44

LUND, Sweden, December 3, 2012 /PRNewswire/ -- NeuroVive announces publication of the results of a Phase I clinical trial of lead product CicloMulsion(R) in the scientific journal Clinical Drug Investigation. The paper highlights that the intravenous cyclosporine formulation CicloMulsion(R) demonstrates bioequivalence and improved tolerability when compared with Sandimmune(R) Injection. The mitochondrial medicine company NeuroVive Pharmaceutical today announces...

2012-11-16 20:21:22

VANCOUVER, Nov. 16, 2012 /PRNewswire/ - Angiotech Pharmaceuticals, Inc. ("Angiotech") announced that its partner Cook Medical, Inc. ("Cook") received approval on November 15, 2012 from the U.S. Food and Drug Administration ("FDA") to market and sell the proprietary Zilver® PTX® drug-eluting peripheral stent, adding the United States to the list of over 50 markets, including the European Union and Japan, where Zilver PTX is approved for sale. Zilver PTX is the first...

2012-11-16 12:26:32

Phase III study results show improvement in overall survival compared to standard treatment SCOTTSDALE, Ariz., Nov. 16, 2012 /PRNewswire-USNewswire/ -- A new cancer drug combination demonstrated significant improvement in overall survival of late-stage pancreatic cancer patients compared to those receiving standard treatment, according to results of a Phase III clinical trial led by physicians from Scottsdale Healthcare's Virginia G. Cancer Center Clinical Trials, a partnership with the...

2012-10-25 07:31:13

MELBOURNE, Australia, Oct. 25, 2012 /PRNewswire/ -- Specialised Therapeutics Australia Pty Ltd today announced that abstracts for the upcoming Society for Melanoma Research meeting have been published online in the organization's official journal at http://onlinelibrary.wiley.com/doi/10.1111/pcmr.12023/abstract. The publication includes an abstract reviewing results from a phase III metastatic melanoma study with ABRAXANE(®) (nanoparticle albumin-bound paclitaxel). In the...

Ovarian Cancer Patients Could Benefit From New Drug
2012-10-04 09:22:49

Connie K. Ho for redOrbit.com — Your Universe Online A new study from scientists at the University of Southern California shows that a new drug could be used to help ovarian cancer patients who have not been receptive to drugs that are currently available and possibly reduce the drug dosage needed to be taken. In particular, the drug has been tested in a lab with ovarian cancer cells and on mice tumors. It is part of a group of cytotoxic agents, known as PACMA, that was discovered...